Colorectal carcinoma: nucleosomes, carcinoembryonic antigen and ca 19-9 as apoptotic markers; a comparative study

Journal of Biomedical Science

Fazlul Huq²  Samir S Mahgoub¹  Jehad M Al-Shuneigat¹ 

[1] Faculty of Medicine, Department of Pharmacology and Biochemistry Mu'tah University, Al Karak, Jordan;Faculty of Medicine, Discipline of Biomedical Science, The University of Sydney, Australia

关键词: tumor marker;    carcinoembryonic antigen (CEA) and CA 19-9;    nucleosomes;    colorectal carcinoma;   

Others  :  833189
DOI  :  10.1186/1423-0127-18-50

 received in 2011-03-02, accepted in 2011-07-25,  发布年份 2011

【 摘 要 】

Background

Colorectal carcinoma is a common and often fatal disease in which methods of early detection and monitoring are essential. The present study was conducted for measuring serum levels of nucleosomes, carcinoembryonic antigen (CEA) and CA 19-9 in patients newly diagnosed with colorectal carcinoma and confirmed by clinicopathological study.

Method

Thirty subjects were included in the current study: six normal subjects as a control group with mean age (45.6 ± 7.9) and twenty four colorectal carcinoma patients with mean age (46.9 ± 15.6), which were classified pathologically according to the degree of malignant cell differentiation into well differentiated (group I), moderately differentiated (group II) and poorly differentiated (group III). Fasting venous blood samples were collected preoperative.

Results

The results revealed a significant increase in serum level of nucleosomes in patients with poorly differentiated tumors versus patients with well differentiated tumors (p = 0.041). The levels of CEA and CA19-9 showed no significant increase (p = 0.569 and 0.450, respectively).

Conclusion

In conclusion, serum level of nucleosomes provides a highly sensitive and specific apoptotic marker for colorectal carcinoma.

【 授权许可】

   
2011 Al-Shuneigat et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Chan CC, Fan CW, Kuo YB, Chen YH, Chang PY, Chen KT, Hung RP, Chan EC: Multiple serological biomarkers for colorectal cancer detection. Int J Cancer 2010, 126:1683-1690.
• [2]Zhao-Hut H, Li-Hua L, Fan Y, Jin-Fu W: Detection of apparent methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol 2007, 14:950-954.
• [3]Ramos M, Esteva M, Cabeza E, Campillo C, Llobera J, Aguilo A: Relationship of diagnostic and therapeutic delay with survival in colorectal cancer: A review. European journal of cancer 2007, 43:2467-2478.
• [4]Ahlquist DA: Molecular Detection of Colorectal Neoplasia. Gastroenterology 2010, 138:2127-2139.
• [5]Osaka A, Hasegawa H, Yamada Y, Yanagihara K, Hayashi T, Mine M, Aoyama M, Sawada T: A novel role of serum cytochrome c as a tumor marker in patients with operable cancer. J Cancer Res Clin Oncol 2009, 135:371-377.
• [6]Holdenrieder S, Stieber P, Boden MH, Busch M, Pawel JV, Schalhom A, Nagel D, Seidel D: Circulating nucleosomes in serum. Ann N Y Acad Sci 2001, 945:93-102.
• [7]Tan ML, Ooi JP, Ismail N, Moad AIH, Muhammad TST: Programmed Cell Death Pathways and Current Antitumor Targets. Pharmaceutical Research 2009, 26:1547-1560.
• [8]Hengartner MO: The biochemistry of apoptosis. Nature 2000, 407:770-774.
• [9]Aleman MJ, De Young MP, Tress M, Ketting P, Perry GW, Nara YR: Inhibition of single minded 2 gene expression mediates tumor - selective apoptosis and differentiation in human colon cancer cells. Proc Natl Acad Sci 2005, 102:12765-12770.
• [10]Remacle-Bonnet M, Garrouste F, Baillat G, Andre F, Marvaldi J, Pommier G: Membrane rafts segregate pro-and anti-apoptotic insulin like growth factor- 1 receptor signaling in colon carcinoma cells stimulated by membranes of tumor necrosis factor superfamily. Am J Pathol 2005, 167:761-773.
• [11]Brandt D, Volkmann X, Anstatt M, Langer F, Manns MP, Schulze-Osthoff K, Bantel H: Serum biomarkers of cell death for monitoring therapy response of gastrointestinal carcinomas. European journal of cancer 2010, 4:1464-1473.
• [12]Holdenrieder S, Stieber P: Apoptotic markers in cancer. Clinical Biochemistry 2004, 37:605-617.
• [13]Van Nieuwenhuijze AEM, Van Lopik T, Smeenk RJT, Aarden LA: Time between onset of apoptosis and release of nucleosomes from apoptotic cells: putative implications for systemic lupus erythematosus. Ann Rheum Dis 2003, 62:10-14.
• [14]Haier J, Nicolson GL: The role of tumor cell adhesion as an important factor in formation of distant colorectal metastasis. Dis Colon Rectum 2001, 44:876-884.
• [15]Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, Peeters M, Penninckx F, Filez L, Bleichrodt RP, Mortelmans L: Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). European Journal of Cancer 2001, 37:862-869.
• [16]Duffy MJ, Van Dalen A, Haglund C, Hansson L, Klapdof R, Lamerz R, Nilsson O, Sturgron C, Toplocan O: Clinical utility of biochemical markers of CRC: European Group on Tumor marker (EGTM) guidelines. Eur J Cancer 2003, 39:718-727.
• [17]Astler VB, Coller FA: The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Sur 1954, 139:846-852.
• [18]Campbell PN, Smith AD: Biochemistry illustrated. Edinburgh: Churchill Livingstone; 2000.
• [19]Zeerleder S, Zwart B, Wuillemin WA, Aarden LA, Groeneveld ABJ, Caliezit C, Van Nieuwenhuijze AEM, Van Mierlo GJ, Eerenberg AJM, Lammle B, Hack CE: Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med 2003, 31:1947-1951.
• [20]Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP: Carcinoembryonic antigen, a human tumor marker, functions as intercellular molecule. Cell 1989, 57:327-334.
• [21]Ueda K, Iwahashi M, Nakamori M: Improvement of carcinoembryonic antigen-specific prodrug gene therapy for experimental.cancer colon. Surgery 2003, 133:309-317.
• [22]He Z, Shi C, Wen H, Li F, Wang B, Wang J: The potential of carcinoembryonic antigen, p53, Ki-67 and glutathione S-transferase-π as clinico-histopathological markers for colorectal cancer. Journal of Biomedical Research 2010, 24:51-57.
• [23]Koroukian SM, Xu F, Dor A, Woper GS: Colorectal cancer screening in the elderly population: disparities by dual Medicare - Medicaid enrollment status. Health Ser Res 2006, 41:2136-2154.
• [24]Zheng CX, Zhan WH, Zhao JZ, Zheng D, Wang DP, He YL, Zheng ZQ: The prognostic value of pre-operative serum levels of CEA, CA 19-9 and CA 72-4 in patients with colorectal cancer. World J Gastroenterol 2001, 7:431-434.
• [25]Holdenrieder S, Nagel D, Schalhorn A, Heinemann V, Wilkowski R, Von Pawel J, Raith H, Feldmann K, Kremer AE, Muller S, Geiger S, Hamann GF, Seidel D, Stieber P: Clinical Relevance of Circulating Nucleosomes in Cancer. Ann N Y Acad Sci 2008, 1137:180-189.
• [26]Wigmore SJ, McMahon AJ, Sturgeon CM, Fearon CH: Acute-phase protein response, survival and tumor recurrence in patients with colorectal cancer. Br J Surg 2001, 88:255-260.
• [27]Shoji Y, Saegusa M, Tanako Y, Ohbu M, Okayasu I: Correlation of apoptosis with tumor cell differentiation, progression and HPV infection in cervical carcinoma. J Clin Pathol 1996, 49:134-138.
• [28]Beere HM, Hickman JA: Differentiation: A suitable strategy for cancer chemotherapy. Anticancer drug Des 1993, 8:299-322.
• [29]Jenab M, Thompson LU: Phytic acid in wheat bran affects colon morphology, cell differentiation and apoptosis. Carcinogenesis 2000, 21:1547-1552.
• [30]Andreas K, Stefan H, Petra S, Ralf W, Dorothea N, Dietrich S: Nucleosomes in colorectal cancer patients during radiochemotherapy. Tumor Biology 2006, 27:235-242.
• [31]Chan DW, Sell S: Tumor markers. In Tietz Textbook of Clinical Chemistry. Edited by Burtis CA, Ashwood ER. Philadelphia: W B Saunders Company; 1999:722-724.
• [32]Bhatnagar J, Tewari H, Bhatnagar M, Austin GE: Comparison of carcinoembryonic antigen in tissue and serum with grade and stage of colon cancer. Anticancer Res 1999, 19:2181-2187.